Action on Hearing Loss Logo
    Total results:
      Total results:
      Research Summit


      A one-day summit that brings together opinion leaders and stakeholders from around the world to share and discuss the biggest challenges and opportunities in the development of treatments for hearing loss and tinnitus.

      9:00 Arrival refreshments

      9:15 Welcome

      Paul Breckell, CEO Action on Hearing Loss
      Prof. Jonathan Gale, Interim Director University College London (UCL) Ear Institute
      Dr. Ralph Holme, Executive Director of Research, Action on Hearing Loss

      Session 1: Clinical trials - the learning curve

      Chair: Prof. Anne Schilder, evidENT, Ear Institute, University College London, NIHR UCLH BRC Deafness and Hearing Problems theme, UK

      9:30 What do patients and clinicians need?

      Prof. Douglas Hartley, Nottingham University, UK

      9:45 Early Phase Trials in Hearing Disorders; Challenges and Opportunities

      Prof. Anne Schilder, evidENT, Ear Institute, University College London, NIHR UCLH BRC Deafness and Hearing Problems theme, UK

      10:00 Questions & Answers: the patient view

      Hugh Strickland, Corporate Finance Partner at Aaron & Partners Solicitors, UK. Hugh suffers from hereditary hearing loss.

      10:20 Morning refreshments and networking

      10:40 Atoh1 gene therapy for hearing loss - preclinical and early clinical development

      Dr. Richard Colvin, Novartis, USA

      11:00 Developing drugs for central hearing loss and tinnitus

      Dr Charles Large, Autifony Therapeutics, UK

      11:20 Targeted drug delivery to treat hearing loss disorders

      Dr Alan C Foster, Otonomy, USA

      11:40 Sodium thiosulfate (STS) as otoprotectant to reduce the incidence of cisplatin-induced hearing loss: final results of the siopel 6 trial for standard risk hepatoblastoma (SR-HB)

      Dr Penelope R. Brock, Retired Consultant Paediatric Oncologist Great Ormond Street Hospital for Children NHS Foundation Trust, UK

      12:00 Lunch and networking

      Session 2: Building on success - opportunities and challenges

      Chair Dr. Carina Santos, Action on Hearing Loss,UK

      1:10 An overview of the mechanisms of hearing loss (and tinnitus) and their potential as therapeutic targets 

      Prof Jonathan Gale, Interim Director UCL Ear Institute

      1:30 Showcase presentations (10 minutes each, without questions)

      • Developing stem cell therapies for the treatment of hearing loss

      Prof. Marcelo Rivolta, Sheffield University, UK

      Targeted somatic cell neurotrophin gene electrotransfer promotes spiral ganglion neurite outgrowth to enhance cochlear implant performance

      Prof. Gary Housley, UNSW Sydney, NSW, Australia 

      • Development of a unique therapeutic approach for the treatment of noise-induced hearing loss: the allosteric modulation of the mGlu7 receptor

      Dr Guillaume Duvey, Pragma Therapeutics, France 

      • Magnetic Delivery of Therapy to the Cochlea

      Dr Benjamin Shapiro, Otomagnetics, USA 

      Development of ORC-13661: A Medicine to Prevent Aminoglycoside-Induced ototoxicity

      Prof. Edwin W Rubel, University of Washington and Oricula Therapeutics Inc, USA 

      A gerbil model to evaluate the effects of drugs on neural correlates of tinnitus and functional hearing 

      Dr Roland Schaette, UCL-Ear Institute, UK 

      • Getting the measure of tinnitus

      Prof. Deborah Hall, University of Nottingham and NIHR Nottingham Briomedical Rsearch Centre, UK 

      • Exploring the views and expectations of patients and Professional stakeholders on novel hearing therapies; a qualitative study.

      Dr. Matthew Topping, evidENT, Ear Institute, UCL, UK

      3:00 Medicines discovery for auditory disease:  Right Drug, Right Dose, Right Time, Right Patient

      Dr. Rick Cousins, GSK, UK 

      3:20 Afternoon refreshments

      3:40 Panel Discussion 

      “How to accelerate the development of biological and pharmacological treatments for hearing loss and tinnitus?”

      Chair Dr Sohaila Rastan, Independent advisor, UK 


      1.Dr Erik Larsen

       Senior Director of Hearing Science and Technology, Decibel Therapeutics, USA

      2. Rolf-Jan Rutten

      CEO Audion Therapeutics, Netherlands

      3. Dr August Wilke

       Principal Research Scientist at Chorus, a Division of Eli Lilly and Company , USA

      4. Prof. Karen Steel

      Professor of Sensory Function at the Wolfson Centre for Age-Related Diseases, King’s College London, UK

      5. Prof. Gary Housley

      Professor of Physiology and Director of the Translational Neuroscience Facility, School of Medical Sciences, UNSW Sydney, Australia

      6. Prof. Deborah Hall

       Professor of Hearing Sciences, Faculty of Medicine & Health Sciences, University of Nottingham; Deputy Director of the NIHR Nottingham Biomedical Research Centre, and Hearing Theme, UK

      7. Dr Ralph Holme

      Executive Director of Research, Action on Hearing Loss, UK

      5:30 Drinks reception and networking


      Summit Report

      Download the report of the summit.


      Summit abstract book

      Download the agenda and abstract book of the summit


      If you have any questions about the summit, please contact our Biomedical Research team.